The largest database of trusted experimental protocols

19 protocols using ly294002

1

Investigating Cyclin D1 Regulation in H. pylori Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
The PI3K inhibitor LY294002 (Enzo Life Science #BML-ST420-005) was used at concentrations of 1, 5 and 10 μM; the Akt inhibitor VIII (Calbiochem #124018) was used at 1 μM and the mTOR inhibitor Rapamycin (Sigma #R8781) at 50 nM. The inhibitors were added to culture media 30 min previous to infection. All inhibitors were solubilized in DMSO.
To determine the Cyclin D1 half-life, the protein synthesis inhibitor cycloheximide (CHX) 100 μg/ml (Sigma #C0934) was added to infected cells after 8 h of exposure to H. pylori and protein extracts were then prepared at the indicated time points after CHX addition.
To determine the role of the proteasome in Cyclin D1 decrease, the proteasome inhibitor MG132 (20 μM) (Enzo Life Science #BML-PI102-005) was added to infected cells after 8 h of infection, in the absence and presence of protein synthesis inhibitor CHX, for 15 min. Then, protein extracts were prepared for western blot analysis.
+ Open protocol
+ Expand
2

Reagents and Inhibitors in Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
Reagents used during cell culture included: Ham's F-12, Dulbecco modified Eagle medium (DMEM), gentamicin, sodium bicarbonate, streptomycin/penicillin, TRI reagent, trypan blue, protease, collagenase, hyaluronidase, and deoxyribonuclease from Sigma-Aldrich Chemical Company (St. Louis, MO); and fetal calf serum (FCS) from Atlanta Biologicals (Atlanta, GA).
The hormones and inhibitors used during cell culture included: ovine FSH (175 × NIH-FSH-S1 U/mg) and ovine LH (NIADDK-NIH-26; AFP5551B) from the National Hormone and Peptide Program (Harbor-UCLA Medical Center, Torrance, CA); testosterone from Steraloids (Newport, RI); recombinant human IGF1 and FGF9 (without carrier protein) from R&D Systems, Inc. (Minneapolis, MN); LY294002 (a PI3K inhibitor), H89 (a PKA inhibitor), U0126 (a MAPK/ERK inhibitor) and wortmannin (a PI3K inhibitor) from Enzo Life Sciences Inc. (Farmingdale, NY).
+ Open protocol
+ Expand
3

Investigating Inflammatory Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell culture supplements were purchased from Invitrogen (Carlsbad, CA, USA). Antibodies against IL-6 (SC-28343), p-p65 (Ser536; SC-101752), p-65 (SC-8008), p-85 (SC-1637), p-AKT (Thr308; SC-16646-R), AKT (SC-5298), p-IKKα/β (Ser180/Ser181; SC-23470-R), IKKα/β(SC-7607), p-IκBα (Ser32; SC-8404), IκBα (SC-203), PCNA(SC-36), and β-actin (SC-58673), and C6 ceramide (an ERK activator), were all purchased from Santa Cruz (Santa Cruz, CA, USA). Anti-TNF-α (a11534) was obtained from Abclonal (Woburn, MA, USA). Antibody against p-p85 (Tyr458/Tyr199; 4228S) was purchased from Cell Signaling (Danvers, MA, USA). AKT inhibitor were supplied by Calbiochem (San Diego, CA, USA). Ly294002, TPCK and PDTC were bought from Enzo Life Sciences International (Plymouth Meeting, PA, USA) and Cell culture supplements were purchased from Invitrogen (Carlsbad, CA, USA). Dual-Luciferase® Reporter Assay System was bought from Promega (Madison, WI, USA). All other chemicals not described above were supplied by Sigma-Aldrich (St Louis, MO, USA).
+ Open protocol
+ Expand
4

Inhibitors and Reagents in Cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following inhibitors or reagents were used in this study: LY294002 (Enzo Life Sciences, USA), MK-2206 (Invitrogen, USA), C3 exoenzyme (Cytoskeleton, USA), and pertussis toxin (PTX; Invitrogen, USA). YAP and phospho-YAP (Ser127) were purchased from Cell Signaling (Cell Signaling technology, USA). CTGF, ANG-2, and GAPDH antibodies were from Santa Cruz Biotechnology (Santa Cruz, USA). Alexafluor secondary antibodies were from Life Technologies, USA.
+ Open protocol
+ Expand
5

Chemotherapeutic Resistance Mechanisms in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Prostate cancer PC3 cells obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and docetaxel‐resistant PC3/Doc cells, as previously described 11, lung adenocarcinoma H460 and paclitaxel‐resistant H460/RT cells, oral epithelium carcinoma KB cells and the vincristine‐resistant KB/VCR cells, murine PCa RM‐1 cells (The Cell Bank of Chinese Academy of Sciences) and RM‐1/Doc cells (docetaxel‐resistant cell line derived from RM‐1) were cultured in RPMI 1640 medium (HyClone, Logan, UT, USA) supplemented with 10% foetal bovine serum (GIBCO, Grand Island, NY, USA), 100 U/ml penicillin and 100 g/ml streptomycin.
Trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), the PI3K inhibitor LY294002, cycloheximide (CHX), actinomycin (Act D) and sodium tauroursodeoxycholate (TUDCA) were purchased from Sigma‐Aldrich (St‐Louis, MO, USA). The pan‐caspase inhibitor Z‐VAD‐fmk was obtained from Enzo Life Sciences (Plymouth Meeting, PA, USA).
In some experiments, the cells were exposed to Z‐VAD‐fmk, CHX, LY294002 or Act D for 2 hrs before TSA treatment. DMSO was used as the control vehicle.
+ Open protocol
+ Expand
6

Wound Healing Assay with MDA-MB 231 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
MDA-MB 231 cells were plated into 24-well plates (105 cells/well) in complete medium. Confluent monolayers were nutrient starved by growing them for 24 h in medium containing 0.5% FBS and then scratched using a 200 μl pipette tip. After washing, cells were treated or not with 10 ng/ml of refp17 or vp17s in complete medium (10% FBS). When reported, starved MDA-MB 231 cells were pretreated with 2.5 μg/ml of mAb to CXCR1 (mAb 330; R&D, Minneapolis, MN, USA) or to CXCR2 (mAb 331; R&D), or with an isotype-matched mAb (2.5 μg/ml; R&D) for 1 h at 37 °C before proteins stimulation. In some experiments, MDA-MB 231 cells were serum starved for 24 h in the presence or absence of inhibitors of PI3K/Akt (LY294002) (20 μM) (ENZO Life Sciences, Farmingdale, NY, USA), Jak/STAT (AG-490) (20 μM) (Sigma-Aldrich, St. Louis, MO, USA) or MEK/ERK1/2 (PD98059) (10 μM) (Calbiochem, Billerica, MA, USA) signaling pathways. Cell migration was evaluated at different time points using an inverted microscope (DM-IRB microscope system, Leica, Buffalo Grove, IL, USA). Cells were photographed using a CCD camera (Hitachi Inc., Krefeld, Germany). Wound closure was monitored over 12 h. In some experiments, in order to count the cells migrating into the wound area or protruding from the border of the wound, cells were fixed before wound closure and stained with Comassie brilliant blue.
+ Open protocol
+ Expand
7

Molecular Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
All chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany), if not indicated otherwise. Rapamycin came from Cell Signaling Technology (Frankfurt, Germany), LY294002 and SB203580 from Enzo Life Science (Lörrach, Germany). Antibodies were obtained from the following sources: anti-Akt and anti-phospho-S6 from Cell Signaling Technology (Frankfurt, Germany), anti-HA from Covance (Munich, Germany), anti-nucleolin from Santa Cruz Biotechnology (Heidelberg, Germany), and IRDyes 680LT and 800CW secondary antibodies from Li-COR Biosciences GmbH (Bad Homburg, Germany).
+ Open protocol
+ Expand
8

Molecular Mechanisms of AKT and GSK-3β Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
For Western blotting analysis, antibodies against AKT (GTX121937), and GAPDH (GTX100118) were purchased from GeneTex (Hsinchu, Taiwan); anti-pAKTS473 (CST4060), anti-GSK-3β (CST9315), and anti-pGSK-3βS9 (CST9323) were purchased from Cell Signaling (Danvers, MA, USA). The PI3K inhibitor LY294002 and Akt inhibitor SH-6 were obtained from Enzo Life Sciences (Farmingdale, NY, USA). CA strains SC5314 and SC5314-GFP were gifts from Dr. Lo Hsiu-Jung (National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Taiwan). A plasmid containing cDNA encoding a GSK-3β mutant GSK-3βS9A was a gift from Scott Friedman lab (Addgene plasmid # 49492; http://n2t.net/addgene:49492; RRID:Addgene_49492). The cDNAs was subcloned into pLentiviral vector to generate lentivirus carrying GSK-3βS9A cDNA. Lentiviral pGIPZ carrying either shRNA vectors targeting human LDOC1 (shLDOC1) or GFP-tagged LDOC1 ORF were purchased from GE Dharmacon (Lafayette, CO, USA).
+ Open protocol
+ Expand
9

Purification and Antibody Validation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Gentisyl alcohol was purified from a culture of Arthrinium spp., KUC21332, as described previously [10 (link)]. Antibodies against phosphorylated ERK1/2 (Thr202/Tyr204, catalog number: 9101), JNK (Thr183/Tyr185, catalog number: 4668), P38 (Thr180/Tyr182, catalog number: 4511), P90RSK (Thr573, catalog number: 9346), AKT (Ser473, catalog number: 4060), P70S6K (Thr421/Ser424, catalog number: 9204), S6 (Ser235/236, catalog number: 2211), and GSK3β (Ser9, catalog number: 9336). Antibodies against total ERK1/2 (catalog number: 4695), JNK (catalog number: 9252), P38 (catalog number: 9212), P90RSK (catalog number: 9335), AKT (catalog number: 9272), P70S6K (catalog number: 9202), S6 (catalog number: 2217), GSK3β (catalog number: 9315) were purchased from Cell Signaling Technology (Beverly, MA, USA). The inhibitors for ERK1/2 (U0126), PI3K/AKT (LY294002), and JNK (SP600125) were obtained from Enzo Life Sciences, Inc. (Farmingdale, NY, USA).
+ Open protocol
+ Expand
10

Kinase Inhibitor Evaluation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lapatinib, OSI-906, jnj38877605, MK2206, and U0126 were purchased from Selleck Chemicals. LY294002 and triciribine were purchased from Enzo Life Sciences. GSK2334470 was purchased from MedChem Express. The following antibodies were purchased from Cell Signaling Technology: phospho-EGFR (#3777), phospho-InsR/IGF1R (#3024), phospho-Met (#3077), phospho-Akt (#4060), phospho-Erk1/2 (#9101), phospho-CRAF (#9427), phospho-IRS1 (#3070) and IRS1 (#2382). phospho-IRS1 (pY632) antibody (ab109543) and vinculin antibody (ab73412) were purchased from Abcam. GAPDH antibody was purchased from Shanghai Kangchen. α-tubulin antibody was purchased from Santa Cruz. And β-actin antibody was purchased from Abmart.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!